A review explored the 3 main administration options for pegfilgrastim biosimilars, finding that providers should consider the ease and frequency to which patients will need to travel to a clinic for administration as well as their preferences when choosing a mode of administration.
Authors of a review article examined administration options and economic considerations for pegfilgrastim biosimilars in supportive oncology in the United States with the aim of maximizing the benefit to patients.
Because of the “growing acceptance of same-day pegfilgrastim administration and the ever-present financial burden of medications for patients,” the authors said, these are pertinent topics. Their review discussed administration options with a focus on minimizing clinic visits and proposed a patient-centric model of pegfilgrastim administration for febrile neutropenia prophylaxis.
The granulocyte colony-stimulating factor (G-CSF) biologics filgrastim and pegfilgrastim are used to reduce the risk of febrile neutropenia in patients undergoing myelosuppressive chemotherapy, by stimulating production, maturation, and survival of neutrophils. According to the authors, febrile neutropenia can delay treatment and necessitate dose reductions, limiting the efficacy of treatments and negatively affecting patient health or reducing survival rates. Of the 2, pegfilgrastim, which is a pegylated, long-acting form of filgrastim, is the most commonly used G-CSF in the United States.
Although the high cost of biologics can limit access to treatments, the authors noted that lower-cost pegfilgrastim biosimilars have been available for several years. There are currently 6 pegfilgrastim biosimilars approved in the US for prophylaxis of febrile neutropenia.
The reviewers wrote that cost savings could have a “significant impact on the financial stress experienced by patients with cancer,” citing research that found up to 48% of cancer survivors experience financial toxicity. They added that financial stress can cause survivors to skip future medical treatments.
Administration Options for Minimizing Clinic Visits
In general, pegfilgrastim is administered once per chemotherapy cycle and is usually injected 24 hours or more after chemotherapy. Although the FDA-approved indication for febrile neutropenia prophylaxis is next-day administration at the clinic, the authors said multiple options are available.
For example, The National Comprehensive Cancer Network also supports same-day administration, which they said has been helpful for minimizing clinic visits during the COVID-19 pandemic. The authors added that same-day administration is likely preferable for patients who live far from the clinic or prefer to minimize visits because of “emotional and physical exhaustion following chemotherapy.”
The reviewers discuss the positives and negatives associated with the 3 approaches to pegfilgrastim administration that minimize clinic visits:
Although self-administration reduces clinic visits and may improve quality of life for patients, correct self-injection techniques are crucial. Barriers to self-injection include fear, anticipated pain, patient age, and comorbidities. The OBI device is applied the same day as chemotherapy and delivers a standard dose of pegfilgrastim 27 hours after application. Failure rates for the OBI range from 1.7% to 6.9%. Not all patients accept the device, and “patient education may be required to ensure the effectiveness of pegfilgrastim OBI and to handle device failure.”
The OBI provides an alternative to self-injection, but OBI devices that deliver biosimilar pegfilgrastim at a lower cost are currently unavailable. According to the authors, 1 pegfilgrastim biosimilar (pegfilgrastim-cbqv) OBI is in development.
The third option for minimizing clinic visits is the off-label use of same-day injection of pegfilgrastim following chemotherapy. This option still eliminates the second clinic visit, and it may be a preferable option for patients who are unable or unwilling to self-inject pegfilgrastim and are uncomfortable having the OBI device attached to their skin.
According to the reviewers, concerns about same-day administration originated from observations that shorter-acting filgrastim could exacerbate neutropenia in some cases.“However, same-day administration of pegfilgrastim is not uncommon in clinical practice, and an increasing number of studies across various tumor types have not detected differences in outcomes compared with next-day administration,” they wrote.
Same-day Pegfilgrastim Administration in the Context of COVID-19
The reviewers said that minimizing clinic visits is an important objective, since patients with cancer have a greater risk of infection compared to healthy individuals, and “frequent hospital visits may further increase the risk of contracting COVID-19 during the current pandemic, especially in immunocompromised older patients with poor functional status.” While the pandemic continues, they said, outpatient visits for patients with cancer should be minimized “without compromising adequate patient care.”
Although same-day administration has not been studied in the context of the COVID-19 pandemic, the authors wrote, “these methods were successfully used before the COVID-19 pandemic and may provide risk-minimization opportunities.” Plus, same-day administration may have an added benefit: “Reducing patient visits can also reduce the workload for health care workers, who are currently overburdened and overworked because of COVID-19.”
The reviewers recommended that the pegfilgrastim administration method “should be based on the patient’s specific needs, while also considering mitigating factors, such as the economic burden associated with biologic medications and the risk of COVID-19.”
Reference
Humphreys SZ, Geller RB, Walden P. Pegfilgrastim biosimilars in US supportive oncology: a narrative review of administration options and economic considerations to maximize patient benefit. Oncol Ther. 2022:1-11. doi: 10.1007/s40487-022-00207-2
Strengthening the Supply Chain: Key Insights From FDA Commissioner Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims
October 23rd 2024At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen industry collaboration, with Sarah Yim, MD, of the FDA, emphasizing education's key role in building trust and adoption.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
IQVIA Webinar: Enhancing Regulatory Strategies for Biosimilars and Generics
October 14th 2024During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies for navigating complex approval processes, the importance of local market understanding, and the role of technology in enhancing submission efficiency.
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.